|

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine, STEMVAC, STEMVAC Th1 Polyepitope Plasmid-based Vaccine

Pipeline

Phase 2: 3

Top Sponsors

  • University of Washington3

Indications

  • Cancer3
  • Anatomic Stage IV Breast Cancer AJCC v82
  • Breast Cancer2
  • Metastatic Hormone Receptor-Positive Breast Carcinoma1
  • Metastatic Triple-Negative Breast Carcinoma1

Seattle, Washington2 trials

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Omaha, Nebraska1 trial

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

University of Nebraska Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.